CARE II - Evaluation of Treatment Outcomes in Schizophrenic Patients Taking Part in the Integrated Care Program - a Single-Country, Multi-Centre Phase IV Study

Trial Profile

CARE II - Evaluation of Treatment Outcomes in Schizophrenic Patients Taking Part in the Integrated Care Program - a Single-Country, Multi-Centre Phase IV Study

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 13 Oct 2012

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Acronyms CARE-II
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Oct 2008 Planned number of patients was 200, the actual number enrolled was 7, according to ClinicalTrials.gov record.
    • 30 Oct 2008 Status changed from not yet recruiting to discontinued according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top